FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3134861807> ?p ?o ?g. }

• W3134861807 endingPage "87" @default.
• W3134861807 startingPage "79" @default.
• W3134861807 abstract "BackgroundThe burden of COVID-19 in patients with bullous pemphigoid (BP) and pemphigus is yet to be evaluated.ObjectiveTo assess the risks of COVID-19 and COVID-19-associated hospitalization and mortality in patients with BP and pemphigus and to delineate determinants of severe COVID-19 illness among these patients.MethodsA population-based cohort study compared COVID-19 and its complications in patients with BP (n = 1845) and pemphigus (n = 1236) with age-, sex-, and ethnicity-matched control subjects.ResultsThe risks of COVID-19 (hazard rate [HR], 1.12; 95% confidence interval [CI], 0.72-1.73; P = .691) and COVID-19-associated hospitalization (HR, 1.58; 95% CI, 0.84-2.98; P = .160) was comparable between patients with BP and controls. The risk of COVID-19-associated mortality was higher among patients with BP (HR, 2.82; 95% CI, 1.15-6.92; P = .023). The risk of COVID-19 (HR, 0.81; 95% CI, 0.44-1.49; P = .496), COVID-19-associated hospitalization (HR, 1.41; 95% CI, 0.53-3.76; P = .499), and COVID-19-associated mortality (HR, 1.33; 95% CI, 0.15-11.92; P = .789) was similar in patients with pemphigus and their controls. Systemic corticosteroids and immunosuppressants did not predispose COVID-19-positive BP and pemphigus patients to a more severe illness.LimitationsRetrospective data collection.ConclusionsPatients with BP experience increased COVID-19-associated mortality and should be monitored closely. Maintaining systemic corticosteroids and immunosuppressive adjuvant agents during the pandemic is not associated with worse outcomes. The burden of COVID-19 in patients with bullous pemphigoid (BP) and pemphigus is yet to be evaluated. To assess the risks of COVID-19 and COVID-19-associated hospitalization and mortality in patients with BP and pemphigus and to delineate determinants of severe COVID-19 illness among these patients. A population-based cohort study compared COVID-19 and its complications in patients with BP (n = 1845) and pemphigus (n = 1236) with age-, sex-, and ethnicity-matched control subjects. The risks of COVID-19 (hazard rate [HR], 1.12; 95% confidence interval [CI], 0.72-1.73; P = .691) and COVID-19-associated hospitalization (HR, 1.58; 95% CI, 0.84-2.98; P = .160) was comparable between patients with BP and controls. The risk of COVID-19-associated mortality was higher among patients with BP (HR, 2.82; 95% CI, 1.15-6.92; P = .023). The risk of COVID-19 (HR, 0.81; 95% CI, 0.44-1.49; P = .496), COVID-19-associated hospitalization (HR, 1.41; 95% CI, 0.53-3.76; P = .499), and COVID-19-associated mortality (HR, 1.33; 95% CI, 0.15-11.92; P = .789) was similar in patients with pemphigus and their controls. Systemic corticosteroids and immunosuppressants did not predispose COVID-19-positive BP and pemphigus patients to a more severe illness. Retrospective data collection. Patients with BP experience increased COVID-19-associated mortality and should be monitored closely. Maintaining systemic corticosteroids and immunosuppressive adjuvant agents during the pandemic is not associated with worse outcomes." @default.
• W3134861807 created "2021-03-15" @default.
• W3134861807 creator A5008417497 @default.
• W3134861807 creator A5021559096 @default.
• W3134861807 creator A5029266042 @default.
• W3134861807 creator A5049241721 @default.
• W3134861807 creator A5067198663 @default.
• W3134861807 creator A5070588042 @default.
• W3134861807 date "2021-07-01" @default.
• W3134861807 modified "2023-10-09" @default.
• W3134861807 title "The risk of COVID-19 in patients with bullous pemphigoid and pemphigus: A population-based cohort study" @default.
• W3134861807 cites W1596092785 @default.
• W3134861807 cites W2000445173 @default.
• W3134861807 cites W2052572274 @default.
• W3134861807 cites W2261662877 @default.
• W3134861807 cites W2414712277 @default.
• W3134861807 cites W2460486510 @default.
• W3134861807 cites W2510325932 @default.
• W3134861807 cites W2576939961 @default.
• W3134861807 cites W2770992251 @default.
• W3134861807 cites W2792283195 @default.
• W3134861807 cites W2792987873 @default.
• W3134861807 cites W2811056062 @default.
• W3134861807 cites W2911256927 @default.
• W3134861807 cites W3012696170 @default.
• W3134861807 cites W3015579738 @default.
• W3134861807 cites W3015890581 @default.
• W3134861807 cites W3016771389 @default.
• W3134861807 cites W3020496963 @default.
• W3134861807 cites W3020646040 @default.
• W3134861807 cites W3022262218 @default.
• W3134861807 cites W3022878099 @default.
• W3134861807 cites W3024016727 @default.
• W3134861807 cites W3024177957 @default.
• W3134861807 cites W3026873778 @default.
• W3134861807 cites W3029557269 @default.
• W3134861807 cites W3030308448 @default.
• W3134861807 cites W3036128399 @default.
• W3134861807 cites W3046992119 @default.
• W3134861807 cites W3048431881 @default.
• W3134861807 cites W3082441865 @default.
• W3134861807 cites W3082474050 @default.
• W3134861807 cites W4206388858 @default.
• W3134861807 cites W4211003831 @default.
• W3134861807 doi "https://doi.org/10.1016/j.jaad.2021.02.087" @default.
• W3134861807 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7968167" @default.
• W3134861807 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33744354" @default.
• W3134861807 hasPublicationYear "2021" @default.
• W3134861807 type Work @default.
• W3134861807 sameAs 3134861807 @default.
• W3134861807 citedByCount "14" @default.
• W3134861807 countsByYear W31348618072021 @default.
• W3134861807 countsByYear W31348618072022 @default.
• W3134861807 countsByYear W31348618072023 @default.
• W3134861807 crossrefType "journal-article" @default.
• W3134861807 hasAuthorship W3134861807A5008417497 @default.
• W3134861807 hasAuthorship W3134861807A5021559096 @default.
• W3134861807 hasAuthorship W3134861807A5029266042 @default.
• W3134861807 hasAuthorship W3134861807A5049241721 @default.
• W3134861807 hasAuthorship W3134861807A5067198663 @default.
• W3134861807 hasAuthorship W3134861807A5070588042 @default.
• W3134861807 hasBestOaLocation W31348618071 @default.
• W3134861807 hasConcept C126322002 @default.
• W3134861807 hasConcept C159654299 @default.
• W3134861807 hasConcept C179755657 @default.
• W3134861807 hasConcept C201903717 @default.
• W3134861807 hasConcept C203014093 @default.
• W3134861807 hasConcept C207103383 @default.
• W3134861807 hasConcept C2778075117 @default.
• W3134861807 hasConcept C2779134260 @default.
• W3134861807 hasConcept C2779252107 @default.
• W3134861807 hasConcept C2781327288 @default.
• W3134861807 hasConcept C2908647359 @default.
• W3134861807 hasConcept C3008058167 @default.
• W3134861807 hasConcept C44249647 @default.
• W3134861807 hasConcept C524204448 @default.
• W3134861807 hasConcept C71924100 @default.
• W3134861807 hasConcept C72563966 @default.
• W3134861807 hasConcept C99454951 @default.
• W3134861807 hasConceptScore W3134861807C126322002 @default.
• W3134861807 hasConceptScore W3134861807C159654299 @default.
• W3134861807 hasConceptScore W3134861807C179755657 @default.
• W3134861807 hasConceptScore W3134861807C201903717 @default.
• W3134861807 hasConceptScore W3134861807C203014093 @default.
• W3134861807 hasConceptScore W3134861807C207103383 @default.
• W3134861807 hasConceptScore W3134861807C2778075117 @default.
• W3134861807 hasConceptScore W3134861807C2779134260 @default.
• W3134861807 hasConceptScore W3134861807C2779252107 @default.
• W3134861807 hasConceptScore W3134861807C2781327288 @default.
• W3134861807 hasConceptScore W3134861807C2908647359 @default.
• W3134861807 hasConceptScore W3134861807C3008058167 @default.
• W3134861807 hasConceptScore W3134861807C44249647 @default.
• W3134861807 hasConceptScore W3134861807C524204448 @default.
• W3134861807 hasConceptScore W3134861807C71924100 @default.
• W3134861807 hasConceptScore W3134861807C72563966 @default.
• W3134861807 hasConceptScore W3134861807C99454951 @default.
• W3134861807 hasIssue "1" @default.
• W3134861807 hasLocation W31348618071 @default.

• next